Initiatives to Advance Drug Discovery labmate-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labmate-online.com Daily Mail and Mail on Sunday newspapers.
May 02 2021 Read 9 Times
An investment of €1M ($1.2M) in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies has been announced by French biotech Calixar. This strategic investment, supported by Bpifrance investment bank, will enable the company to provide native and functional membrane therapeutic targets (GPCRs, ion channels, transporters, receptors and viral targets) and advance drugs and vaccines developments.
“Collective studies agree that the pharmaceutical industry needs to optimise its drug development model,” said Emmanuel Dejean, founder and CEO of Calixar. “In Calixar’s view, the problems faced in clinical development are related particularly to the unreliability of the therapeutic targets isolated upstream.”